ProQR Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell PRQR and other ETFs, options, and stocks.About PRQR
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J.
PRQR Key Statistics
Stock Snapshot
With a market cap of 191.73M, ProQR Therapeutics(PRQR) trades at $1.82. The stock has a price-to-earnings ratio of -4.00.
On 2026-03-14, ProQR Therapeutics(PRQR) stock moved within a range of $1.73 to $1.85. With shares now at $1.82, the stock is trading +5.2% above its intraday low and -1.6% below the session's peak.
Trading activity shows a volume of 524.45K, compared to an average daily volume of 347.64K.
Over the past 52 weeks, ProQR Therapeutics(PRQR) stock has traded between a high of $3.10 and a low of $1.07.
Over the past 52 weeks, ProQR Therapeutics(PRQR) stock has traded between a high of $3.10 and a low of $1.07.
PRQR News
ProQR Therapeutics BV (PRQR) has disclosed a new risk, in the Share Price & Shareholder Rights category. ProQR Therapeutics BV faces heightened risk from stock...
ProQR ( (PRQR) ) just unveiled an update. On March 12, 2026, ProQR reported its operating and financial results for the year ended Dec. 31, 2025, highlighting...
Oppenheimer analyst Kostas Biliouris assumed coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $9 price target The firm sees a lot to like for...
Analyst ratings
100%
of 9 ratingsMore PRQR News
At December 31, 2025, ProQR held cash and cash equivalents of approximately EUR 92.4 million, compared to EUR 149.4 million at December 31, 2024. “2025 was a ye...